Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases

In the phase III DESTINY-Breast03 trial, trastuzumab deruxtecan improved progression-free survival (PFS) relative to trastuzumab emtansine across all patients with HER2-positive metastatic breast cancer, including a 75% improvement in PFS among those with baseline brain metastases.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963137/
https://www.ncbi.nlm.nih.gov/pubmed/35348784
http://dx.doi.org/10.1093/oncolo/oyac009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963137/
https://www.ncbi.nlm.nih.gov/pubmed/35348784
http://dx.doi.org/10.1093/oncolo/oyac009

Ejemplares similares